Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Freedom of information applications as an "evergreening" tactic: Secretary, Department of Health and Ageing v iNOVA Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442

dc.contributor.authorFaunce, Thomasen_AU
dc.date.accessioned2015-12-10T22:36:21Z
dc.date.issued2011
dc.date.updated2016-02-24T10:31:14Z
dc.description.abstractA recent decision of the Federal Court of Australia illustrates how patent-holding pharmaceutical companies are attempting to use Australia's Freedom of Information Act 1982 (Cth) to force Australian safety, quality and efficacy regulators to disclose whether generic competitors are attempting to enter the market. In Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442 a single judge of the Federal Court overturned a decision of the Administrative Appeals Tribunal (AAT) that would have compelled the Australian Therapeutic Goods Administration (TGA) to reveal whether they were in possession of an application to register generic versions of two iNova products: imiquimod and phentermine. In its justification to the AAT for refusing to confirm or deny the existence of any application, the TGA argued that to reveal the existence of such a document would prejudice the proper administration of the National Health Act 1953 (Cth) as it could compromise the listing of a generic on the Pharmaceutical Benefits Scheme. The AAT failed to appreciate the extent to which this revelation to a competitor would have undercut 2004 amendments to the Therapeutic Goods Act 1989 (Cth) that provided penalties for evergreening tactics involving TGA notifications to drug patent-holders and 2006 amendments to the Patents Act 1990 (Cth) which protected the right of generic manufacturers to "springboard". The decision of the Federal Court is one of the first to explore the use of freedom of information legislation by patent-holders as a potential "evergreening" technique to prolong royalties by marginalising generic competition. Because of the significant amounts of money involved in ensuring rapid market entry of low-cost generic products, the issue has considerable public health significance.
dc.identifier.issn1320-159X
dc.identifier.urihttp://hdl.handle.net/1885/56648
dc.provenanceThe permission to archive the version was archived in ERMS2988179. This article was first published by Thomson Reuters in the Journal of Law and Medicine and should be cited as "Vines, Timothy, and Thomas Alured Faunce. "Freedom of Information Applications as An'Evergreening'Tactic." Journal of law and medicine 19.1 (2011): 43-52.". For all subscription inquiries please phone, from Australia: 1300 304 195, from Overseas: +61 2 8587 7980 or online at legal.thomsonreuters.com.au/search. The official PDF version of this article can also be purchased separately from Thomson Reuters at http://sites.thomsonreuters.com.au/journals/subscribe-or-purchaseen_AU
dc.publisherThe Law Book Company
dc.rightsCopyright Lawbook Co. This publication is copyright. Other than for the purposes of and subject to the conditions prescribed under the Copyright Act 1968 (Cth), no part of it may in any form or by any means (electronic, mechanical, microcopying, photocopying, recording or otherwise) be reproduced, stored in a retrieval system or transmitted without prior written permission. Enquiries should be addressed to Thomson Reuters (Professional) Australia Limited.en_AU
dc.sourceJournal of Law and Medicine
dc.subjectKeywords: generic drug; access to information; article; Australia; drug industry; human; legal aspect; patent; Access to Information; Australia; Drug Industry; Drugs, Generic; Humans; Patents as Topic
dc.titleFreedom of information applications as an "evergreening" tactic: Secretary, Department of Health and Ageing v iNOVA Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442
dc.typeJournal article
dcterms.accessRightsOpen Accessen_AU
local.bibliographicCitation.issue43
local.bibliographicCitation.lastpage52
local.bibliographicCitation.startpage43
local.contributor.affiliationFaunce, Thomas, ANU College of Law, ANU
local.contributor.authoruidFaunce, Thomas, u9705219
local.description.notesImported from ARIES
local.identifier.absfor180123 - Litigation, Adjudication and Dispute Resolution
local.identifier.absfor111599 - Pharmacology and Pharmaceutical Sciences not elsewhere classified
local.identifier.ariespublicationu4046278xPUB370
local.identifier.citationvolume19
local.identifier.scopusID2-s2.0-80155202724
local.type.statusPublished Version

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Faunce_Freedom_of_information_2011.pdf
Size:
83.21 KB
Format:
Adobe Portable Document Format